Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TVT 2016

TVT 1146: First-in-Man Experience of Using the Aegis Surgical Transit (TM) System for Suprasternal TAVR Using a Self-Expanding Valve

Presenter: John P Vavalle, MD, MHS, FACC

June 17, 2016

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation

Optimal Catchment Area, Primary PCI Center Volume Revisited: A Single-Center Experience in Transition From High-Volume to “Mega Center” for STEMI

Presenter: Mikkel Malby Schoos

December 28, 2014

Presentation TCT 2014

Bendavia to Prevent Mitochondrial Transition Pore Opening

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Amir Lerman, C. Michael Gibson

September 16, 2014

Presentation TCT 2014

Experimental Requirements and Device Validation: Critical Changes Impacting Transition to Human Testing

Presenter: Alexandre Abizaid, Elazer R. Edelman, Greg L. Kaluza

September 16, 2014

Presentation TCT 2014

Translational Research in Transition: Emerging Tools and Methods for Validation of Device Performance

Presenter: Alexandre Abizaid, Elazer R. Edelman, Dawn Bardot

September 16, 2014

Presentation Scripps 2013

Tips and Tricks for Transitioning Your Lab to Radial

Presenter: Paul S. Teirstein

October 02, 2013

Presentation Transradial 2013

Transitioning to Radial

Presenter: Paul Teirstein

June 28, 2013

Presentation TCT 2013

Neurological complications following PCI - incidence and trends during a period of transition from femoral to radial access. Observational data from the British Cardiovascular...

Presenter: Karim Ratib, Mamas Mamas, Adrian Large, Samer Arnous, Helen Routledge, Peter Ludman, Doug Fraser, Jim Nolan

January 31, 2013

Presentation TCT 2012

Building a Niche: How to Transition from the "New" Interventionalist to the "Expert"

Presenter: James Zidar

October 26, 2012

Presentation TCT 2012

TCT-32. Neurological Complications Following PCI - Incidence and Trends During a Period of Transition from Femoral to Radial Access. Observational Data from the British...

Presenter: Karim Ratib

October 23, 2012

Presentation TCT 2012

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Presenter: Paul S. Rees, Sean M. Davidson, Sian E. Harding, Perry M. Elliott, Derek J. Hausenloy, Derek M. Yellon

January 03, 2012

Advertisement

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

FDA Perspectives

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

TVT 1146: First-in-Man Experience of Using the Aegis Surgical Transit (TM) System for Suprasternal TAVR Using a Self-Expanding Valve

Cangrelor IV: Transitioning to Oral ADP Antagonists

Optimal Catchment Area, Primary PCI Center Volume Revisited: A Single-Center Experience in Transition From High-Volume to “Mega Center” for STEMI

Bendavia to Prevent Mitochondrial Transition Pore Opening

Experimental Requirements and Device Validation: Critical Changes Impacting Transition to Human Testing

Translational Research in Transition: Emerging Tools and Methods for Validation of Device Performance

Tips and Tricks for Transitioning Your Lab to Radial

Transitioning to Radial

Neurological complications following PCI - incidence and trends during a period of transition from femoral to radial access. Observational data from the British Cardiovascular...

Building a Niche: How to Transition from the "New" Interventionalist to the "Expert"

TCT-32. Neurological Complications Following PCI - Incidence and Trends During a Period of Transition from Femoral to Radial Access. Observational Data from the British...

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content